Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization

References

• Frantz R, Huang S, Are A and Motaparthi K. (2021). Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina, 57(9), 895 10.3390/medicina57090895
   PubMedGoogle Scholar
• Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol. 1987;123(9):1160–1165. [published Online First: Epub Date]|. Doi:10.1001/archderm.123.9.1160.
   PubMedGoogle Scholar
• Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol. 2017;177(4):924–935. [published Online First: Epub Date]|. Doi:10.1111/bjd.15360.
   PubMed Web of Science ®Google Scholar
• Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020;9:612. [published Online First: Epub Date]|. Doi:10.12688/f1000research.24748.
   Google Scholar
• Bastuji-Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92–96.
   PubMedGoogle Scholar
• Tartarone A, Lerose R. Stevens-Johnson syndrome and toxic epidermal necrolysis: what do we know? Ther Drug Monit. 2010;32(6):669–672. [published Online First: Epub Date]|. Doi:10.1097/FTD.0b013e3181f2f24f.
   PubMed Web of Science ®Google Scholar
• Duong TA, Valeyrie-Allanore L, Wolkenstein P, et al. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390(10106):1996–2011. [published Online First: Epub Date]|. Doi:10.1016/s0140-6736(16)30378-6.
   PubMed Web of Science ®Google Scholar
• Egunsola O, Star K, Juhlin K, et al. Retrospective review of paediatric case reports of Stevens-Johnson syndrome and toxic epidermal necrolysis with lamotrigine from an international pharmacovigilance database. BMJ Paediatr Open. 2017;1(1):e000039. [published Online First: Epub Date]|. Doi:10.1136/bmjpo-2017-000039.
   PubMedGoogle Scholar
• Johnson DB, Manouchehri A, Haugh AM, et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019 1;7(1):134. [published Online First: Epub Date]|. Doi:10.1186/s40425-019-0617-x.
   PubMed Web of Science ®Google Scholar
• Zhai Y, Ye X, Hu F, et al. Cardiovascular toxicity of Carfilzomib: the real-world evidence based on the adverse event reporting system database of the FDA, the United States. Front Cardiovasc Med. 2021;8:735466. [published Online First: Epub Date]|. Doi:10.3389/fcvm.2021.735466.
   PubMed Web of Science ®Google Scholar
• Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther. 2007;82(2):157–166. [published Online First: Epub Date]|. Doi:10.1038/sj.clpt.6100258.
   PubMed Web of Science ®Google Scholar
• Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69. [published Online First: Epub Date]|. Doi:10.1177/0962280211403604.
   PubMed Web of Science ®Google Scholar
• Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74(13):1667–1678. [published Online First: Epub Date]. Doi:10.1016/j.jacc.2019.07.056.
   PubMed Web of Science ®Google Scholar
• Kubota K, Koide D, Hirai T. Comparison of data mining methodologies using Japanese spontaneous reports. Pharmacoepidemiol Drug Saf. 2004;13(6):387–394. [published Online First: Epub Date]. Doi:10.1002/pds.964.
   PubMed Web of Science ®Google Scholar
• Ang PS, Chen Z, Chan CL, et al. Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures. Expert Opin Drug Saf. 2016;15(5):583–590. [published Online First: Epub Date]|. Doi:10.1517/14740338.2016.1167184.
   PubMed Web of Science ®Google Scholar
• Li C, Xia J, Deng J, et al. A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China. Pharmacoepidemiol Drug Saf. 2008;17(6):593–600. [published Online First: Epub Date]. Doi:10.1002/pds.1601.
   PubMed Web of Science ®Google Scholar
• FDA Drug Label. 2022 Jan 14. https://dailymed.nlm.nih.gov/dailymed/index.cfm
   Google Scholar
• EMC Drug Label. 2022 Jan 14. https://www.medicines.org.uk/emc/
   Google Scholar
• Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428(6982):486. [published Online First: Epub Date]|. Doi:10.1038/428486a.
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–4139. [published Online First: Epub Date]|. Doi:10.1073/pnas.0409500102.
   PubMed Web of Science ®Google Scholar
• Somkrua R, Eickman EE, Saokaew S, et al. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet. 2011;12(1):118. [published Online First: Epub Date]. Doi:10.1186/1471-2350-12-118.
   PubMedGoogle Scholar
• Ferrell PB Jr., McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9(10):1543–1546. [published Online First: Epub Date]. Doi:10.2217/14622416.9.10.1543.
   PubMed Web of Science ®Google Scholar